China Cord Blood Corporation (NYSE:CO) was the target of a significant decrease in short interest in the month of September. As of September 29th, there was short interest totalling 249,561 shares, a decrease of 50.2% from the September 15th total of 501,050 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 252,533 shares, the days-to-cover ratio is presently 1.0 days.

Shares of China Cord Blood Corporation (NYSE:CO) opened at 10.90 on Wednesday. China Cord Blood Corporation has a one year low of $4.27 and a one year high of $14.95. The firm has a market capitalization of $1.24 billion, a P/E ratio of 34.82 and a beta of 0.89. The firm has a 50-day moving average of $11.91 and a 200-day moving average of $9.90.

China Cord Blood Corporation (NYSE:CO) last issued its earnings results on Wednesday, August 23rd. The medical research company reported $0.09 earnings per share (EPS) for the quarter. China Cord Blood Corporation had a return on equity of 8.64% and a net margin of 22.07%. The firm had revenue of $33.07 million for the quarter. On average, equities analysts predict that China Cord Blood Corporation will post $0.15 earnings per share for the current fiscal year.

Separately, BidaskClub raised shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 1st.

A number of institutional investors and hedge funds have recently modified their holdings of CO. Renaissance Technologies LLC boosted its holdings in China Cord Blood Corporation by 6.5% during the first quarter. Renaissance Technologies LLC now owns 859,500 shares of the medical research company’s stock worth $5,724,000 after buying an additional 52,700 shares during the last quarter. Parametrica Management Ltd bought a new position in China Cord Blood Corporation during the second quarter worth about $149,000. Acadian Asset Management LLC boosted its holdings in China Cord Blood Corporation by 5.5% during the second quarter. Acadian Asset Management LLC now owns 622,995 shares of the medical research company’s stock worth $5,904,000 after buying an additional 32,592 shares during the last quarter. Spark Investment Management LLC boosted its holdings in China Cord Blood Corporation by 273.9% during the second quarter. Spark Investment Management LLC now owns 114,800 shares of the medical research company’s stock worth $1,088,000 after buying an additional 84,100 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in China Cord Blood Corporation during the second quarter worth about $948,000. Hedge funds and other institutional investors own 13.33% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/18/short-interest-in-china-cord-blood-corporation-co-drops-by-50-2.html.

China Cord Blood Corporation Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with MarketBeat.com's FREE daily email newsletter.